- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Novel Vaccine Added to Chemotherapy Improves Patient Outcomes in Mesothelioma
April 15th 2016, 6:21am
The first report of results from a phase Ib clinical trial evaluating CRS-207, a live, attenuated, double-deleted Listeria monocytogenes vaccine, in combination with pemetrexed and cisplatin, demonstrated the effectiveness of this approach for patients with malignant pleural mesothelioma.
Third-Generation EGFR TKIs Move to Frontline in Lung Cancer
April 14th 2016, 1:44pm
A new generation of EGFR-targeted TKIs are poised to displace traditional agents as frontline therapies for patients with lung cancer.
Dr. John Haanen on the Role of PD-L1 in Lung Cancer
April 14th 2016, 1:21pm
John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.
Aligning Physician Compensation to Value Is No Easy Task
April 14th 2016, 12:39pm
Aligning physician compensation to performance can be a dicey matter, as it is difficult to reach a consensus on how to measure physician success. However, a number of oncology practices have been developing systems for doing this and achieving success.
Frontline Osimertinib Approaches 80% Response in EGFR+ NSCLC
April 14th 2016, 11:33am
First-line treatment with single-agent osimertinib (Tagrisso) induced a response rate of 77% in patients with EGFR-mutated non–small cell lung cancer.
Dr. Thierry Jahan on CRS-207 With Chemotherapy in Mesothelioma
April 14th 2016, 11:21am
Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses CRS-20, a live, attenuated Listeria monocytogenes bacterium which is being investigated with chemotherapy in malignant pleural mesothelioma (MPM).
High Response Rates Observed With BI-1482694 in T790M+ NSCLC
April 14th 2016, 11:19am
Patients with non-small cell lung cancer who had ceased to respond to EGFR TKI therapy demonstrated a rapid and robust response to the investigational agent BI-1482694 (HM61713).
Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines
April 4th 2016, 1:15pm
William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.
NCCN Introduces New Vulvar Cancer Guideline
April 4th 2016, 12:28pm
A new NCCN guideline for the management of vulvar cancer outlines the use of resection, radiation therapy, and chemotherapy based on disease site and stage, recognizing that only 2 randomized treatment trials have been completed.
Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL
April 4th 2016, 9:57am
Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).
NCCN Refines Recommendations for Breast Cancer Care
April 2nd 2016, 4:12pm
At the 2016 NCCN Annual Conference, William J. Gradishar, MD, discussed updates to the NCCN Breast Cancer Guideline and the latest research developments in the field.
TKIs Dominate NCCN Update in EGFR+ NSCLC
April 2nd 2016, 3:16pm
Testing for EGFR mutations should be routine in patients with non–small cell lung cancer. With the presence of an EGFR mutation TKIs are an appropriate treatment option across multiple lines of therapy, according to the latest update from the NCCN.
Optimizing Current Treatments for CLL as New Agents Are Investigated
April 2nd 2016, 1:52pm
Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.
NCCN Broadens Myeloma Diagnostic Criteria, Recommends Novel Agents
April 2nd 2016, 1:24pm
The updated NCCN myeloma guideline broadens the diagnostic criteria for active disease and integrates novel therapies into the treatment paradigm.
Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines
April 2nd 2016, 11:05am
Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.
Dr. Anderson on How the Definition of Myeloma Has Changed
April 2nd 2016, 5:08am
Kenneth C. Anderson, MD, Giant of Cancer Care: Myeloma, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how the definition of myeloma has changed.
NCCN Readies Practitioners for Tapping the Potential of Biosimilars
April 1st 2016, 2:38pm
While biosimilars have the potential to create competition and result in healthcare savings, the path to the marketplace has proven complex.
Dr. Salerno Discusses Hypofractionation for Early Breast Cancer
April 1st 2016, 11:18am
Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.
NCCN Guideline Expands Locoregional Treatment Candidates in HCC
April 1st 2016, 8:36am
Locoregional therapies are now considered potentially curable options that should be considered alongside transplant and resection for patients with hepatocellular carcinoma.
Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines
April 1st 2016, 8:06am
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines.